The Borrelia hermsii factor H binding protein FhbA is not required for infectivity in mice or for resistance to human complement in vitro

The primary causative agent of tick-borne relapsing fever in North America is Borrelia hermsii. It has been hypothesized that B. hermsii evades complement-mediated destruction by binding factor H (FH), a host-derived negative regulator of complement. In vitro, B. hermsii produces a single FH binding...

Full description

Saved in:
Bibliographic Details
Published inInfection and immunity Vol. 82; no. 8; pp. 3324 - 3332
Main Authors Fine, Lindy M, Miller, Daniel P, Mallory, Katherine L, Tegels, Brittney K, Earnhart, Christopher G, Marconi, Richard T
Format Journal Article
LanguageEnglish
Published United States American Society for Microbiology 01.08.2014
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The primary causative agent of tick-borne relapsing fever in North America is Borrelia hermsii. It has been hypothesized that B. hermsii evades complement-mediated destruction by binding factor H (FH), a host-derived negative regulator of complement. In vitro, B. hermsii produces a single FH binding protein designated FhbA (FH binding protein A). The properties and ligand binding activity of FhbA suggest that it plays multiple roles in pathogenesis. It binds plasminogen and has been identified as a significant target of a B1b B cell-mediated IgM response in mice. FhbA has also been explored as a potential diagnostic antigen for B. hermsii infection in humans. The ability to test the hypothesis that FhbA is a critical virulence factor in vivo has been hampered by the lack of well-developed systems for the genetic manipulation of the relapsing fever spirochetes. In this report, we have successfully generated a B. hermsii fhbA deletion mutant (the B. hermsii YORΔfhbA strain) through allelic exchange mutagenesis. Deletion of fhbA abolished FH binding by the YORΔfhbA strain and eliminated cleavage of C3b on the cell surface. However, the YORΔfhbA strain remained infectious in mice and retained resistance to killing in vitro by human complement. Collectively, these results indicate that B. hermsii employs an FhbA/FH-independent mechanism of complement evasion that allows for resistance to killing by human complement and persistence in mice.
AbstractList The primary causative agent of tick-borne relapsing fever in North America is Borrelia hermsii . It has been hypothesized that B. hermsii evades complement-mediated destruction by binding factor H (FH), a host-derived negative regulator of complement. In vitro , B. hermsii produces a single FH binding protein designated FhbA (FH binding protein A). The properties and ligand binding activity of FhbA suggest that it plays multiple roles in pathogenesis. It binds plasminogen and has been identified as a significant target of a B1b B cell-mediated IgM response in mice. FhbA has also been explored as a potential diagnostic antigen for B. hermsii infection in humans. The ability to test the hypothesis that FhbA is a critical virulence factor in vivo has been hampered by the lack of well-developed systems for the genetic manipulation of the relapsing fever spirochetes. In this report, we have successfully generated a B. hermsii fhbA deletion mutant (the B. hermsii YORΔ fhbA strain) through allelic exchange mutagenesis. Deletion of fhbA abolished FH binding by the YORΔ fhbA strain and eliminated cleavage of C3b on the cell surface. However, the YORΔ fhbA strain remained infectious in mice and retained resistance to killing in vitro by human complement. Collectively, these results indicate that B. hermsii employs an FhbA/FH-independent mechanism of complement evasion that allows for resistance to killing by human complement and persistence in mice.
The primary causative agent of tick-borne relapsing fever in North America is Borrelia hermsii. It has been hypothesized that B. hermsii evades complement-mediated destruction by binding factor H (FH), a host-derived negative regulator of complement. In vitro, B. hermsii produces a single FH binding protein designated FhbA (FH binding protein A). The properties and ligand binding activity of FhbA suggest that it plays multiple roles in pathogenesis. It binds plasminogen and has been identified as a significant target of a B1b B cell-mediated IgM response in mice. FhbA has also been explored as a potential diagnostic antigen for B. hermsii infection in humans. The ability to test the hypothesis that FhbA is a critical virulence factor in vivo has been hampered by the lack of well-developed systems for the genetic manipulation of the relapsing fever spirochetes. In this report, we have successfully generated a B. hermsii fhbA deletion mutant (the B. hermsii YOR Delta fhbA strain) through allelic exchange mutagenesis. Deletion of fhbA abolished FH binding by the YOR Delta fhbA strain and eliminated cleavage of C3b on the cell surface. However, the YOR Delta fhbA strain remained infectious in mice and retained resistance to killing in vitro by human complement. Collectively, these results indicate that B. hermsii employs an FhbA/FH-independent mechanism of complement evasion that allows for resistance to killing by human complement and persistence in mice.
ABSTRACT The primary causative agent of tick-borne relapsing fever in North America is Borrelia hermsii . It has been hypothesized that B. hermsii evades complement-mediated destruction by binding factor H (FH), a host-derived negative regulator of complement. In vitro , B. hermsii produces a single FH binding protein designated FhbA (FH binding protein A). The properties and ligand binding activity of FhbA suggest that it plays multiple roles in pathogenesis. It binds plasminogen and has been identified as a significant target of a B1b B cell-mediated IgM response in mice. FhbA has also been explored as a potential diagnostic antigen for B. hermsii infection in humans. The ability to test the hypothesis that FhbA is a critical virulence factor in vivo has been hampered by the lack of well-developed systems for the genetic manipulation of the relapsing fever spirochetes. In this report, we have successfully generated a B. hermsii fhbA deletion mutant (the B. hermsii YORΔ fhbA strain) through allelic exchange mutagenesis. Deletion of fhbA abolished FH binding by the YORΔ fhbA strain and eliminated cleavage of C3b on the cell surface. However, the YORΔ fhbA strain remained infectious in mice and retained resistance to killing in vitro by human complement. Collectively, these results indicate that B. hermsii employs an FhbA/FH-independent mechanism of complement evasion that allows for resistance to killing by human complement and persistence in mice.
The primary causative agent of tick-borne relapsing fever in North America is Borrelia hermsii. It has been hypothesized that B. hermsii evades complement-mediated destruction by binding factor H (FH), a host-derived negative regulator of complement. In vitro, B. hermsii produces a single FH binding protein designated FhbA (FH binding protein A). The properties and ligand binding activity of FhbA suggest that it plays multiple roles in pathogenesis. It binds plasminogen and has been identified as a significant target of a B1b B cell-mediated IgM response in mice. FhbA has also been explored as a potential diagnostic antigen for B. hermsii infection in humans. The ability to test the hypothesis that FhbA is a critical virulence factor in vivo has been hampered by the lack of well-developed systems for the genetic manipulation of the relapsing fever spirochetes. In this report, we have successfully generated a B. hermsii fhbA deletion mutant (the B. hermsii YORΔfhbA strain) through allelic exchange mutagenesis. Deletion of fhbA abolished FH binding by the YORΔfhbA strain and eliminated cleavage of C3b on the cell surface. However, the YORΔfhbA strain remained infectious in mice and retained resistance to killing in vitro by human complement. Collectively, these results indicate that B. hermsii employs an FhbA/FH-independent mechanism of complement evasion that allows for resistance to killing by human complement and persistence in mice.
Author Marconi, Richard T
Tegels, Brittney K
Mallory, Katherine L
Earnhart, Christopher G
Miller, Daniel P
Fine, Lindy M
Author_xml – sequence: 1
  givenname: Lindy M
  surname: Fine
  fullname: Fine, Lindy M
  organization: Department of Microbiology and Immunology, Virginia Commonwealth University Medical Center, Richmond, Virginia, USA
– sequence: 2
  givenname: Daniel P
  surname: Miller
  fullname: Miller, Daniel P
  organization: Department of Microbiology and Immunology, Virginia Commonwealth University Medical Center, Richmond, Virginia, USA
– sequence: 3
  givenname: Katherine L
  surname: Mallory
  fullname: Mallory, Katherine L
  organization: Department of Microbiology and Immunology, Virginia Commonwealth University Medical Center, Richmond, Virginia, USA
– sequence: 4
  givenname: Brittney K
  surname: Tegels
  fullname: Tegels, Brittney K
  organization: Department of Microbiology and Immunology, Virginia Commonwealth University Medical Center, Richmond, Virginia, USA
– sequence: 5
  givenname: Christopher G
  surname: Earnhart
  fullname: Earnhart, Christopher G
  organization: Department of Microbiology and Immunology, Virginia Commonwealth University Medical Center, Richmond, Virginia, USA
– sequence: 6
  givenname: Richard T
  surname: Marconi
  fullname: Marconi, Richard T
  email: rmarconi@vcu.edu
  organization: Department of Microbiology and Immunology, Virginia Commonwealth University Medical Center, Richmond, Virginia, USA Center for the Study of Biological Complexity, Virginia Commonwealth University Medical Center, Richmond, Virginia, USA rmarconi@vcu.edu
BackLink https://www.ncbi.nlm.nih.gov/pubmed/24866803$$D View this record in MEDLINE/PubMed
BookMark eNpVkU1v3CAQhlGVqtmkvfVcceyhTvkyxpdKm6hpVorUS3pGGA8xlQ0bwJHyE_qvyzZplEggYOaZl4H3BB2FGAChj5ScUcrU1912d0ao6llDxRu0oaRXTdsydoQ2hNC-6VvZHaOTnH_XoxBCvUPHTCgpFeEb9OdmAnweU4LZGzxBWrL32BlbYsJXePBh9OEW71Ms4AO-nIYt9hmHWHCCu9UnGLGrqA8ObPH3vjzUPV68BVzDh1SC7HMxoUZKxNO6mIBtXPYzLBDKga5VKb5Hb52ZM3x4Wk_Rr8vvNxdXzfXPH7uL7XVjhSSl6YZBctIxWd9opOhGN3KhutbQXlLlut4qSTgHxQYgLa8T-joEc844BpKfom-Puvt1WGC0tYdkZr1PfjHpQUfj9etM8JO-jfdaUC4ZYVXg85NAincr5KIXny3MswkQ16xpK-tHU961Ff3yiNoUc07gnq-hRB_c09U9_c89TUXFP71s7Rn-bxf_C9yxmR8
CitedBy_id crossref_primary_10_3389_fcimb_2019_00290
crossref_primary_10_3389_fimmu_2020_01560
crossref_primary_10_3389_fimmu_2021_602277
crossref_primary_10_1093_jme_tjw171
crossref_primary_10_1371_journal_ppat_1010338
crossref_primary_10_3109_1040841X_2014_972336
crossref_primary_10_3389_fimmu_2017_00571
crossref_primary_10_3389_fimmu_2017_00012
crossref_primary_10_3389_fmicb_2017_00328
crossref_primary_10_1371_journal_pone_0147707
Cites_doi 10.3201/eid1507.090223
10.1371/journal.ppat.1003308
10.1128/IAI.69.1.446-455.2001
10.1016/S1567-5769(00)00041-2
10.1128/IAI.69.9.5832-5839.2001
10.4269/ajtmh.2002.66.753
10.1086/516273
10.3201/eid1303.060958
10.1007/978-1-4614-5404-5_3
10.1128/IAI.71.6.3597-3602.2003
10.1016/j.imlet.2009.07.005
10.1016/j.molimm.2010.05.007
10.1074/jbc.M007994200
10.1128/IAI.74.5.3030-3034.2006
10.1016/j.molimm.2008.06.028
10.1128/iai.63.7.2478-2484.1995
10.1128/JB.05037-11
10.1128/JB.180.18.4974-4981.1998
10.1002/eji.200323571
10.1074/jbc.M111.323287
10.1128/JCM.41.8.3905-3910.2003
10.1042/bst0300971
10.1016/S0092-8674(00)80298-6
10.1128/JCM.39.7.2500-2507.2001
10.1128/jcm.33.9.2427-2434.1995
10.1016/S0140-6736(06)68968-X
10.1128/IAI.00377-06
10.1128/IAI.69.12.7800-7809.2001
10.1128/IAI.01266-07
10.1371/journal.pntd.0000698
10.1128/IAI.01544-08
10.1086/516276
10.1128/JB.186.9.2612-2618.2004
10.1128/IAI.74.4.2007-2014.2006
10.3109/00016349709024361
10.4049/jimmunol.178.11.7292
10.3201/eid0909.030280
10.4161/hv.4661
10.1128/mr.50.4.381-400.1986
10.1086/514496
10.1128/IAI.00007-06
10.1016/j.vaccine.2008.11.015
10.1111/j.1365-2958.2006.05122.x
ContentType Journal Article
Copyright Copyright © 2014, American Society for Microbiology. All Rights Reserved.
Copyright © 2014, American Society for Microbiology. All Rights Reserved. 2014 American Society for Microbiology
Copyright_xml – notice: Copyright © 2014, American Society for Microbiology. All Rights Reserved.
– notice: Copyright © 2014, American Society for Microbiology. All Rights Reserved. 2014 American Society for Microbiology
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QL
7T5
C1K
H94
5PM
DOI 10.1128/IAI.01892-14
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Bacteriology Abstracts (Microbiology B)
Immunology Abstracts
Environmental Sciences and Pollution Management
AIDS and Cancer Research Abstracts
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
AIDS and Cancer Research Abstracts
Immunology Abstracts
Bacteriology Abstracts (Microbiology B)
Environmental Sciences and Pollution Management
DatabaseTitleList
AIDS and Cancer Research Abstracts
CrossRef
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1098-5522
Editor Blanke, S. R.
Editor_xml – sequence: 1
  givenname: S. R.
  surname: Blanke
  fullname: Blanke, S. R.
EndPage 3332
ExternalDocumentID 10_1128_IAI_01892_14
24866803
Genre Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NIDCR NIH HHS
  grantid: F31 DE023000
– fundername: NIDCR NIH HHS
  grantid: F31-DE023000
– fundername: NIDCR NIH HHS
  grantid: R01-DE017401
– fundername: NIAID NIH HHS
  grantid: R01 AI037787
– fundername: NCATS NIH HHS
  grantid: UL1 TR000058
– fundername: NCATS NIH HHS
  grantid: UL1TR000058
– fundername: NIAID NIH HHS
  grantid: R01-AI037787
– fundername: NIDCR NIH HHS
  grantid: R01 DE017401
GroupedDBID ---
-DZ
-~X
.55
.GJ
0R~
18M
29I
2WC
39C
3O-
4.4
41~
53G
5GY
5RE
5VS
85S
ABOCM
ACGFO
ADBBV
AENEX
AGCDD
AGVNZ
AI.
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BTFSW
C1A
CGR
CS3
CUY
CVF
D0S
DIK
DU5
E3Z
EBS
ECM
EIF
EJD
F5P
FRP
GX1
H13
HYE
HZ~
H~9
IH2
J5H
KQ8
L7B
MVM
NEJ
NPM
O9-
OHT
OK1
P2P
RHF
RHI
RNS
RPM
RSF
SJN
TR2
TWZ
UCJ
UPT
VH1
VQA
W2D
W8F
WH7
WHG
WOQ
X7M
Y6R
ZGI
ZXP
~KM
AAYXX
CITATION
7QL
7T5
C1K
H94
5PM
ID FETCH-LOGICAL-c460t-7bb630726552a647dfd34875a19618f79c86033e82be053e05e95e942ffaf2e63
IEDL.DBID RPM
ISSN 0019-9567
IngestDate Tue Sep 17 21:08:48 EDT 2024
Wed Jul 24 15:15:29 EDT 2024
Thu Sep 12 20:08:51 EDT 2024
Sat Sep 28 07:54:05 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 8
Language English
License Copyright © 2014, American Society for Microbiology. All Rights Reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c460t-7bb630726552a647dfd34875a19618f79c86033e82be053e05e95e942ffaf2e63
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Present address: Lindy M. Fine, University of Maryland Center for Environmental Science, Cambridge, Maryland, USA.
OpenAccessLink https://iai.asm.org/content/iai/82/8/3324.full.pdf
PMID 24866803
PQID 1560141375
PQPubID 23462
PageCount 9
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_4136202
proquest_miscellaneous_1560141375
crossref_primary_10_1128_IAI_01892_14
pubmed_primary_24866803
PublicationCentury 2000
PublicationDate 2014-08-01
PublicationDateYYYYMMDD 2014-08-01
PublicationDate_xml – month: 08
  year: 2014
  text: 2014-08-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: 1752 N St., N.W., Washington, DC
PublicationTitle Infection and immunity
PublicationTitleAlternate Infect Immun
PublicationYear 2014
Publisher American Society for Microbiology
Publisher_xml – name: American Society for Microbiology
References 21551306 - J Bacteriol. 2011 Jul;193(13):3241-5
9455525 - Clin Infect Dis. 1998 Jan;26(1):151-64
17513779 - J Immunol. 2007 Jun 1;178(11):7292-301
18674818 - Mol Immunol. 2008 Oct;45(16):4057-63
20532227 - PLoS Negl Trop Dis. 2010;4(6):e698
5813010 - J Immunol. 1969 Mar;102(3):533-43
16861638 - Infect Immun. 2006 Aug;74(8):4519-29
7494041 - J Clin Microbiol. 1995 Sep;33(9):2427-34
19388168 - Vaccine. 2008 Dec 30;26 Suppl 8:I67-74
3540570 - Microbiol Rev. 1986 Dec;50(4):381-400
12616490 - Eur J Immunol. 2003 Mar;33(3):697-707
9455520 - Clin Infect Dis. 1998 Jan;26(1):122-31
17552097 - Emerg Infect Dis. 2007 Mar;13(3):436-42
20580090 - Mol Immunol. 2010 Aug;47(13):2187-97
16815378 - Lancet. 2006 Jul 1;368(9529):37-43
11113124 - J Biol Chem. 2001 Mar 16;276(11):8427-35
12440956 - Biochem Soc Trans. 2002 Nov;30(Pt 6):971-8
15090501 - J Bacteriol. 2004 May;186(9):2612-8
9351408 - Acta Obstet Gynecol Scand. 1997 Oct;76(9):834-8
23637600 - PLoS Pathog. 2013;9(4):e1003308
16790790 - Infect Immun. 2006 Jul;74(7):4157-63
12904415 - J Clin Microbiol. 2003 Aug;41(8):3905-10
9215633 - Cell. 1997 Jun 27;89(7):1111-9
9733706 - J Bacteriol. 1998 Sep;180(18):4974-81
7790059 - Infect Immun. 1995 Jul;63(7):2478-84
9243047 - Clin Infect Dis. 1997 Jul;25(1):139-44
22451663 - J Biol Chem. 2012 May 25;287(22):18831-42
11500461 - Infect Immun. 2001 Sep;69(9):5832-9
19616581 - Immunol Lett. 2009 Sep 22;126(1-2):1-7
12761145 - Infect Immun. 2003 Jun;71(6):3597-602
16622245 - Infect Immun. 2006 May;74(5):3030-4
19204088 - Infect Immun. 2009 Apr;77(4):1417-25
19624916 - Emerg Infect Dis. 2009 Jul;15(7):1026-31
18299341 - Infect Immun. 2008 May;76(5):2113-22
11367524 - Int Immunopharmacol. 2001 Mar;1(3):393-401
16552029 - Infect Immun. 2006 Apr;74(4):2007-14
16629672 - Mol Microbiol. 2006 May;60(3):710-22
17921702 - Hum Vaccin. 2007 Nov-Dec;3(6):281-9
11427560 - J Clin Microbiol. 2001 Jul;39(7):2500-7
12224586 - Am J Trop Med Hyg. 2002 Jun;66(6):753-8
14519254 - Emerg Infect Dis. 2003 Sep;9(9):1151-4
4999095 - J Immunol. 1971 Sep;107(3):742-50
11119536 - Infect Immun. 2001 Jan;69(1):446-55
11705962 - Infect Immun. 2001 Dec;69(12):7800-9
e_1_3_2_26_2
e_1_3_2_27_2
e_1_3_2_48_2
e_1_3_2_28_2
e_1_3_2_29_2
e_1_3_2_41_2
e_1_3_2_40_2
e_1_3_2_20_2
e_1_3_2_43_2
e_1_3_2_21_2
e_1_3_2_42_2
e_1_3_2_22_2
e_1_3_2_45_2
e_1_3_2_23_2
e_1_3_2_44_2
e_1_3_2_24_2
e_1_3_2_47_2
e_1_3_2_25_2
e_1_3_2_46_2
Felsenfeld O (e_1_3_2_12_2) 1971
McDowell JV (e_1_3_2_14_2) 2012
e_1_3_2_9_2
e_1_3_2_15_2
e_1_3_2_38_2
e_1_3_2_8_2
e_1_3_2_16_2
e_1_3_2_37_2
e_1_3_2_7_2
e_1_3_2_6_2
e_1_3_2_39_2
e_1_3_2_19_2
e_1_3_2_30_2
e_1_3_2_32_2
e_1_3_2_10_2
e_1_3_2_31_2
e_1_3_2_5_2
e_1_3_2_11_2
e_1_3_2_34_2
e_1_3_2_4_2
e_1_3_2_33_2
e_1_3_2_13_2
e_1_3_2_36_2
e_1_3_2_2_2
e_1_3_2_35_2
Cutler S (e_1_3_2_3_2) 2003; 69
Ruddy S (e_1_3_2_18_2) 1971; 107
Ruddy S (e_1_3_2_17_2) 1969; 102
References_xml – ident: e_1_3_2_11_2
  doi: 10.3201/eid1507.090223
– ident: e_1_3_2_31_2
  doi: 10.1371/journal.ppat.1003308
– ident: e_1_3_2_39_2
  doi: 10.1128/IAI.69.1.446-455.2001
– ident: e_1_3_2_29_2
  doi: 10.1016/S1567-5769(00)00041-2
– ident: e_1_3_2_41_2
  doi: 10.1128/IAI.69.9.5832-5839.2001
– ident: e_1_3_2_7_2
  doi: 10.4269/ajtmh.2002.66.753
– ident: e_1_3_2_8_2
  doi: 10.1086/516273
– ident: e_1_3_2_10_2
  doi: 10.3201/eid1303.060958
– start-page: 43
  volume-title: The pathogenic spirochetes: strategies for evasion of host immunity and persistence
  year: 2012
  ident: e_1_3_2_14_2
  doi: 10.1007/978-1-4614-5404-5_3
  contributor:
    fullname: McDowell JV
– ident: e_1_3_2_24_2
  doi: 10.1128/IAI.71.6.3597-3602.2003
– ident: e_1_3_2_32_2
  doi: 10.1016/j.imlet.2009.07.005
– ident: e_1_3_2_16_2
  doi: 10.1016/j.molimm.2010.05.007
– volume: 69
  start-page: 542
  year: 2003
  ident: e_1_3_2_3_2
  article-title: Tick-borne relapsing fever in Tanzania—a forgotten problem?
  publication-title: ASM News
  contributor:
    fullname: Cutler S
– volume-title: Warren H. Green, Inc.
  year: 1971
  ident: e_1_3_2_12_2
  contributor:
    fullname: Felsenfeld O
– volume: 102
  start-page: 533
  year: 1969
  ident: e_1_3_2_17_2
  article-title: C3 inactivator of man. I. Hemolytic measurement by the inactivation of cell-bound C3
  publication-title: J. Immunol.
  contributor:
    fullname: Ruddy S
– ident: e_1_3_2_21_2
  doi: 10.1074/jbc.M007994200
– ident: e_1_3_2_48_2
  doi: 10.1128/IAI.74.5.3030-3034.2006
– ident: e_1_3_2_45_2
  doi: 10.1016/j.molimm.2008.06.028
– ident: e_1_3_2_46_2
  doi: 10.1128/iai.63.7.2478-2484.1995
– volume: 107
  start-page: 742
  year: 1971
  ident: e_1_3_2_18_2
  article-title: C3b inactivator of man. II. Fragments produced by C3b inactivator cleavage of cell-bound or fluid phase C3b
  publication-title: J. Immunol.
  contributor:
    fullname: Ruddy S
– ident: e_1_3_2_34_2
  doi: 10.1128/JB.05037-11
– ident: e_1_3_2_37_2
  doi: 10.1128/JB.180.18.4974-4981.1998
– ident: e_1_3_2_22_2
  doi: 10.1002/eji.200323571
– ident: e_1_3_2_47_2
  doi: 10.1074/jbc.M111.323287
– ident: e_1_3_2_28_2
  doi: 10.1128/JCM.41.8.3905-3910.2003
– ident: e_1_3_2_33_2
  doi: 10.1042/bst0300971
– ident: e_1_3_2_40_2
  doi: 10.1016/S0092-8674(00)80298-6
– ident: e_1_3_2_35_2
  doi: 10.1128/JCM.39.7.2500-2507.2001
– ident: e_1_3_2_36_2
  doi: 10.1128/jcm.33.9.2427-2434.1995
– ident: e_1_3_2_6_2
  doi: 10.1016/S0140-6736(06)68968-X
– ident: e_1_3_2_26_2
  doi: 10.1128/IAI.00377-06
– ident: e_1_3_2_23_2
  doi: 10.1128/IAI.69.12.7800-7809.2001
– ident: e_1_3_2_27_2
  doi: 10.1128/IAI.01266-07
– ident: e_1_3_2_43_2
  doi: 10.1371/journal.pntd.0000698
– ident: e_1_3_2_30_2
  doi: 10.1128/IAI.01544-08
– ident: e_1_3_2_13_2
  doi: 10.1086/516276
– ident: e_1_3_2_19_2
  doi: 10.1128/JB.186.9.2612-2618.2004
– ident: e_1_3_2_25_2
  doi: 10.1128/IAI.74.4.2007-2014.2006
– ident: e_1_3_2_5_2
  doi: 10.3109/00016349709024361
– ident: e_1_3_2_20_2
  doi: 10.4049/jimmunol.178.11.7292
– ident: e_1_3_2_9_2
  doi: 10.3201/eid0909.030280
– ident: e_1_3_2_38_2
  doi: 10.4161/hv.4661
– ident: e_1_3_2_2_2
  doi: 10.1128/mr.50.4.381-400.1986
– ident: e_1_3_2_4_2
  doi: 10.1086/514496
– ident: e_1_3_2_44_2
  doi: 10.1128/IAI.00007-06
– ident: e_1_3_2_15_2
  doi: 10.1016/j.vaccine.2008.11.015
– ident: e_1_3_2_42_2
  doi: 10.1111/j.1365-2958.2006.05122.x
SSID ssj0014448
Score 2.2572005
Snippet The primary causative agent of tick-borne relapsing fever in North America is Borrelia hermsii. It has been hypothesized that B. hermsii evades...
ABSTRACT The primary causative agent of tick-borne relapsing fever in North America is Borrelia hermsii . It has been hypothesized that B. hermsii evades...
The primary causative agent of tick-borne relapsing fever in North America is Borrelia hermsii . It has been hypothesized that B. hermsii evades...
SourceID pubmedcentral
proquest
crossref
pubmed
SourceType Open Access Repository
Aggregation Database
Index Database
StartPage 3324
SubjectTerms Animals
Blood Bactericidal Activity
Borrelia - genetics
Borrelia - immunology
Borrelia hermsii
Carrier Proteins - genetics
Carrier Proteins - metabolism
Complement System Proteins - immunology
Disease Models, Animal
Gene Deletion
Humans
Mice
Molecular Pathogenesis
Relapsing Fever - immunology
Relapsing Fever - microbiology
Virulence Factors - genetics
Virulence Factors - metabolism
Title The Borrelia hermsii factor H binding protein FhbA is not required for infectivity in mice or for resistance to human complement in vitro
URI https://www.ncbi.nlm.nih.gov/pubmed/24866803
https://search.proquest.com/docview/1560141375
https://pubmed.ncbi.nlm.nih.gov/PMC4136202
Volume 82
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Na9wwEB2ygZZeSpp-ZJs0TKE9encty5J83IQuuy0b0tCU3IxkycSQtUPWOfQn9F9nJNuhaW8F-2JJxnhG0hvmaR7AJ-ZiabmmmRY7G3Gb6EjPUh0VqXQp5yZVHcv3TCwv-der9GoH0uEsTCDtF6aa1DebSV1dB27l7aaYDjyx6fn6lBZeQUH7dAQjmSRDiN6nDjjn_fKbRQT-5cB2Z2q6mq8ms1hlLIq9Hg_jSgg1yGUNW9I_OPNvuuQf-89iD172wBHn3Qe-gh1X78OzTkry1z48X_dJ8tfwm0yPJ15146bSSDbZbKsKF0FYB5d4UoWDLHjuKzRUNS6uzRxXWzxrWrxwnhjsLBKUxVXH0_LiEkj91rSkID32TRdu63EnOQy2DYZEAPqVpeOi00j8WbV3zRu4XHz5cbqMesWFqOBi1kbSGEGTnok0ZVpwaUub-IhGx14YppRZocQsSZxixktK0O0yujgrS10yJ5K3sFs3tTsAJBxkRMl4IcuYW6uNYrI0NsksYcQsK8bwefjp-W1XWCMPAQlTOdkpD3aiwGQMHweL5OT5Pp2ha9fcb3N_BjwmV5DpGN51Fnp802DaMcgntnvs4KtqP20hZwvVtXvnev_fIw_hBaEq3rEEj2C3vbt3Hwi5tOYYRt--q-Pgrw-0Y-2o
link.rule.ids 230,315,733,786,790,891,27955,27956,53825,53827
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb5wwEB6lqfq49JG2yfbpSu0RdjF-wHETdbW02VUUJVFuyMZGQc1ClGUP7T_ov-4YcNSkp1aCC7YRaMbjb-TP8wF8ojaShimcaZE1ATOxCtSEq6Dg0nLGNE96lu9SzE_Z13N-vgXcn4XpSPuFrsL6chXW1UXHrbxaFWPPExsfLQ4w8ApM2sf34D7OV8p9kj5sHjDGhgCcBgj_pee702ScTbNwEiUpDSKnyENZIkTiBbP8ovQX0rxLmPxjBZo9hTP_7T3x5Hu4aXVY_LxT1vGff-4ZPBkwKZn2zc9hy9Y78KBXqfyxAw8Xw_77C_iFXkX2naDHZaUImnu1rioy6zR7yJzsV90ZGXLkij9UNZld6CnJ1mTZtOTYOs6xNQRRMsl6CpjTrSDYb4HRiuBj13Rs1w7Soi-StiHdHgNxQaunueNIcla1181LOJ19OTmYB4OYQ1AwMWkDqbXAeEIF51QJJk1pYpcsqchpzpQyLRIxiWObUO3UKvC2KV6MlqUqqRXxK9ium9ruAUGIpUVJWSHLiBmjdEJlqU2cGoSfaVqM4LO3Zn7V1-zIu1yHJjk6QN45AOY8I_joTZ3jpHI7Jaq2zWadu-PlERpC8hHs9qa_eZP3mRHIW05x08EV7L7dgqbuCncPpn393yM_wKP5yeIwP8yW397AYwRvrCcjvoXt9npj3yFAavX7bjr8BqM_Dqo
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagiIpLC4XCUgqDBMckG8exk-O2NNoAu1pVFFVcIjt21IhusupmD-Uf8K8Z51G15VYpucR2lGgentF8no-QT9T4QjOJluYb7TAdSEeOQ-nkoTAhYyqMOpTvnE_P2Nfz8PwW1VcL2s9V6VaXS7cqL1ps5WqZewNOzFvMjtHxckzavZUuvMfkCdosFUOi3hcQGGO9E44dTAHEgHmnkZdOUnfsRzF1fMvKQ1nEeTSQZg0b03_R5n3Q5K1dKNklv4bv78Anv91No9z8z73Wjg_6wedkp49NYdJNeUEemWqPPO3YKq_3yPasr8O_JH9Ru-DIEntclhJQ7Mt1WULScvfAFI7K9qwMLGwTiLKC5EJNIF3DvG7g1FjssdGA0TKkHRTM8lcAzpuh1wJ8bIdOzdqGtqiT0NTQ1hrAOq8O7o4r4WfZXNWvyFly8uN46vSkDk7O-LhxhFIc_QrlYUglZ0IXOrBJk_Qt90wh4jzi4yAwEVWWtQJvE-PFaFHIghoe7JOtqq7MGwIYaileUJaLwmdaS4VqUCgdxBrD0DjOR-TzINFs1fXuyNqch0YZKkHWKgHmPiPycRB3hsZlKyayMvVmndlj5j4KQ4Qj8roT_82bBr0ZEXFHMW4m2Mbdd0dQ3G0D7168bx-88gPZXnxJsu_p_NsBeYYxHOswie_IVnO1MYcYJzXqfWsR_wApXhEq
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Borrelia+hermsii+factor+H+binding+protein+FhbA+is+not+required+for+infectivity+in+mice+or+for+resistance+to+human+complement+in+vitro&rft.jtitle=Infection+and+immunity&rft.au=Fine%2C+Lindy+M&rft.au=Miller%2C+Daniel+P&rft.au=Mallory%2C+Katherine+L&rft.au=Tegels%2C+Brittney+K&rft.date=2014-08-01&rft.eissn=1098-5522&rft.volume=82&rft.issue=8&rft.spage=3324&rft_id=info:doi/10.1128%2FIAI.01892-14&rft_id=info%3Apmid%2F24866803&rft.externalDocID=24866803
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0019-9567&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0019-9567&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0019-9567&client=summon